Invention:
This invention describes a set of novel molecules that target and degrade DYRK/CLK for several potential therapeutic purposes.
Background:
Proteolysis-targeting chimeric molecules (PROTACs) are small molecules used to decrease a gene’s protein expression by targeting the protein for ubiquitination and degradation after it is created. This mechanism has applications in a range of therapeutics. One class of targets with therapeutic potential is the DYRK/CLK class of proteins. DYRK/CLK is associated with severity of COVID-19 infections, glioblastoma, and cognitive impairment such as Alzheimer’s Disease.
In this technology, the inventors purpose a novel set of PROTACS molecules that target DYRK/CLK for ubiquitination and degradation for a range of potential therapeutic applications. The ligand that is tethered through a variety of linkers to an E3-ligase recruiter is novel relative to other PROTACs.
Applications:
- Therapeutic potential against:
- Severe COVID-19 infection
- Cognitive disorders such as Alzheimer’s Disease
- Glioblastoma
Advantages:
- Novel PROTAC
- High specificity
- Broad range of applications
